<DOC>
	<DOC>NCT02899299</DOC>
	<brief_summary>The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.</brief_summary>
	<brief_title>Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Males and Females at least 18 years of age Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery ECOG Performance status of 0 or 1 Available tumor sample for testing Acceptable blood work Primitive peritoneal, pericardial and tunica vaginalis testis mesotheliomas Prior chemotherapy for pleural mesothelioma Prior treatment with an antiPD1, antiPDL1, antiPDL2 orantiCTLA4 antibody History of other malignancy unless the subject has been diseasefree for at least 3 years Active, untreated central nervous system (CNS) metastasis Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>